Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...

Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Although not all bats carry rabies, the city's health department wants people to seek post-exposure prophylaxis if they were bitten, scratched, or had contact with a bat. Meanwhile, travelers from ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

In the current market environment, investors might be more interested in generating income rather than capital gains. Today, ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

RSV vaccine sales by GSK and Pfizer have dropped in the U.S. after regulators limited the eligible age group, affecting ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga ...